Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE. Reinisch W, et al. Among authors: katz s. Inflamm Bowel Dis. 2010 Feb;16(2):233-42. doi: 10.1002/ibd.21038. Inflamm Bowel Dis. 2010. PMID: 19637334 Clinical Trial.
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US. Sands BE, et al. Among authors: katz s. Gastroenterology. 1999 Jul;117(1):58-64. doi: 10.1016/s0016-5085(99)70550-0. Gastroenterology. 1999. PMID: 10381910 Clinical Trial.
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV Jr, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Sandborn WJ, et al. Among authors: katz j, katz s. Aliment Pharmacol Ther. 2003 Jun 1;17(11):1355-64. doi: 10.1046/j.1365-2036.2003.01589.x. Aliment Pharmacol Ther. 2003. PMID: 12786629 Clinical Trial.
A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R. Burakoff R, et al. Among authors: katz s. Inflamm Bowel Dis. 2006 Jul;12(7):558-65. doi: 10.1097/01.ibd.0000225337.14356.31. Inflamm Bowel Dis. 2006. PMID: 16804392 Clinical Trial.
Small bowel adenocarcinoma in Crohn's disease.
Feldstein RC, Sood S, Katz S. Feldstein RC, et al. Among authors: katz s. Inflamm Bowel Dis. 2008 Aug;14(8):1154-7. doi: 10.1002/ibd.20393. Inflamm Bowel Dis. 2008. PMID: 18275076 Review.
3,431 results